跳至主要内容
临床试验/NCT01613521
NCT01613521终止不适用

Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2012年6月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
3
试验地点
1
主要终点
predict tumor response

研究概览

简要总结

This study is to assess how patients respond to their treatment for cervical cancer. This research does not involve a specific treatment for the cancer that will be recommended by the doctor and may include radiation therapy and/or chemotherapy. This is a separate research imaging study designed to assess how patients respond to their treatment for cervical cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Biopsy-documented, newly-diagnosed primary cervical cancer of all histopathology types.
  • Clinically visible gross lesion (International Federation of Gynecology and Obstetrics (FIGO) stage IB1 and above).
  • Treatment (chemoradiation), DCE-MRI and 18F-FMISO PET studies will be at MSKCC.
  • Patients must be an adult female 18 years of age or older.

排除标准

  • Patients who because of general medical or psychiatric condition, or physiologic status cannot give an informed consent.
  • Patients who received prior radiation treatment to pelvis.
  • Patients with contraindications to DCE-MRI (non-compatible cardiac pacemakers or intracranial vascular clips, allergy to Gadolinium, end-stage renal disease) and/or 18F-FMISO PET.
  • Patients who do not fulfill the screening criteria for safe DCE-MRI or 18F-FMISO PET as per the Department of Radiology guidelines.
  • Pregnant patients; and or patients who are breast-feeding their babies.

结局指标

主要结局

predict tumor response

时间窗: 2 years

For each DCE-MRI parameter, the relative percent change from baseline to the two-week measurement will be calculated. These values will be assessed using ROC curves to evaluate whether they are predictive of tumor response.

次要结局

  • predict disease-free survival(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验